In Vivo Metabolism of Pulmonary Surfactant in Infants

婴儿肺表面活性剂的体内代谢

基本信息

  • 批准号:
    6886704
  • 负责人:
  • 金额:
    $ 25.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-05-01 至 2008-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Scanned from the applicant's description): Respiratory distress syndrome (RDS) in infants most commonJy results from a quantitative deficiency of pulmonary surfactant after premature birth. Failure of exogenous surfactant replacement to reconstitute pulmonary function in up to 50 percent of infants with RDS suggests that mechanisms unrelated to quantitative deficiencies in pulmonary surfactant may disrupt surfactant metabolism in a subgroup of infants with lethal RDS. Preliminary data from studies utilizing naturally occurring, stable, non-radioactive isotope labeled metabolic precursors of phospholipid synthesis suggest two alternative mechanisms, which depend on estimates of the surfactant pool size, for disrupted surfactant metabolism in lethal RDS: 1) if surfactant pool sizes are smaller in infants with lethal RDS than in those with non-lethal RDS, then infants with lethal RDS have decreased endogenous surfactant production and/or increased surfactant catabolism; or 2) if surfactant pool sizes are similar, then infants with lethal RDS have increased surfactant production and catabolism. Exogenous surfactant enriched with 2H4-choline labeled phosphatidylcholine and intravenous infusions of surfactant phospholipid precursors (administered as U-13C6]glucose, 7,7,8,8-2H4-palmitate, or 1-13C1acetate) and gas chromatography/mass spectrometry (GCJMS) and gas chromatography-combustion interface isotope ratio mass spectrometry (GC-IRMS) will be used to test the hypothesis that: Increased surfactant catabolism characterizes infants with Lethal RDS. To compare surfactant pool sizes in infants with lethal and non-lethal RDS, 2H4-choline enrichment in surfactant obtained from tracheal aspirate samples after intratracheal administration of labeled surfactant will be measured. To compare surfactant production in infants with lethal and non-lethal RDS, the rate of incorporation of 13C and 2H4 into surfactant obtained from tracheal aspirate samples after a 24 hour infusion of 1-13C1acetate and 7,7,8,8-2H4-palmitate will be measured. To compare surfactant catabolism in infants with lethal and non-lethal RDS, the rate of clearance of 13C and 2H4 from surfactant obtained from tracheal aspirate samples will be measured. Premature infants less than 29 weeks gestation, infants less than 1 year of age with refractory respiratory failure who are awaiting lung transplantation, and infants less than 6 months of age with normal lungs who require mechanical ventilation will be studied. Techniques using labeled metabolic precursors of surfactant phospholipid synthesis provide a unique and powerful approach to evaluate disruption of surfactant metabolism and will lead to specific and clinically useful interventions to restore pulmonary function in infants with RDS.
描述:(扫描自申请人描述):呼吸窘迫

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Decreased surfactant phosphatidylcholine synthesis in neonates with congenital diaphragmatic hernia during extracorporeal membrane oxygenation.
先天性膈疝新生儿在体外膜氧合过程中表面活性剂磷脂酰胆碱合成减少。
  • DOI:
    10.1007/s00134-009-1564-7
  • 发表时间:
    2009
  • 期刊:
  • 影响因子:
    38.9
  • 作者:
    Janssen,DaphneJ;Zimmermann,LucJ;Cogo,Paola;Hamvas,Aaron;Bohlin,Kajsa;Luijendijk,IngridH;Wattimena,Darcos;Carnielli,VirgilioP;Tibboel,Dick
  • 通讯作者:
    Tibboel,Dick
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AARON HAMVAS其他文献

AARON HAMVAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AARON HAMVAS', 18)}}的其他基金

Neonatal Research Network: the Lurie Children's - Northwestern University Study Center
新生儿研究网络:卢里儿童 - 西北大学研究中心
  • 批准号:
    10682322
  • 财政年份:
    2023
  • 资助金额:
    $ 25.6万
  • 项目类别:
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk
早产相关通气控制中自主生物标志物的综合分析:神经呼吸成熟度的确定和共病风险的预测因子
  • 批准号:
    9170046
  • 财政年份:
    2016
  • 资助金额:
    $ 25.6万
  • 项目类别:
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk
早产相关通气控制中自主生物标志物的综合分析:神经呼吸成熟度的确定和共病风险的预测因子
  • 批准号:
    9763356
  • 财政年份:
    2016
  • 资助金额:
    $ 25.6万
  • 项目类别:
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk
早产相关通气控制中自主生物标志物的综合分析:神经呼吸成熟度的确定和共病风险的预测因子
  • 批准号:
    10006025
  • 财政年份:
    2016
  • 资助金额:
    $ 25.6万
  • 项目类别:
PROGRESSIVE LUNG DISEASE AND SURFACTANT DYSFUNCTION WITH A DELETION OF SURFACT
进行性肺病和表面活性剂功能障碍(表面活性剂缺失)
  • 批准号:
    7355212
  • 财政年份:
    2006
  • 资助金额:
    $ 25.6万
  • 项目类别:
PULMONARY DYSFUNCTION & INTEGRITY OF PULMONARY SURFACTANT SYSTEM
肺功能障碍
  • 批准号:
    7180070
  • 财政年份:
    2005
  • 资助金额:
    $ 25.6万
  • 项目类别:
PROGRESSIVE LUNG DISEASE AND SURFACTANT DYSFUNCTION WITH A DELETION OF SURFACT
进行性肺病和表面活性剂功能障碍(表面活性剂缺失)
  • 批准号:
    7180175
  • 财政年份:
    2005
  • 资助金额:
    $ 25.6万
  • 项目类别:
PULMONARY DYSFUNCTION & INTEGRITY OF PULMONARY SURFACTANT SYSTEM
肺功能障碍
  • 批准号:
    6977040
  • 财政年份:
    2003
  • 资助金额:
    $ 25.6万
  • 项目类别:
In Vivo Metabolism of Pulmonary Surfactant in Infants
婴儿肺表面活性剂的体内代谢
  • 批准号:
    6331907
  • 财政年份:
    2001
  • 资助金额:
    $ 25.6万
  • 项目类别:
In Vivo Metabolism of Pulmonary Surfactant in Infants
婴儿肺表面活性剂的体内代谢
  • 批准号:
    6537856
  • 财政年份:
    2001
  • 资助金额:
    $ 25.6万
  • 项目类别:

相似海外基金

'What then do I love, when I love my God?': Divine personae and the human subject in the devotional culture of late fourteenth-century Yorkshire.
“当我爱我的上帝时,我爱什么呢?”:十四世纪末约克郡虔诚文化中的神圣人物和人类主体。
  • 批准号:
    2742225
  • 财政年份:
    2022
  • 资助金额:
    $ 25.6万
  • 项目类别:
    Studentship
Human Subject Core
人类主体核心
  • 批准号:
    10574519
  • 财政年份:
    2021
  • 资助金额:
    $ 25.6万
  • 项目类别:
Human Subject Core
人类主体核心
  • 批准号:
    10596985
  • 财政年份:
    2021
  • 资助金额:
    $ 25.6万
  • 项目类别:
Human Subject Core
人类主体核心
  • 批准号:
    10360441
  • 财政年份:
    2021
  • 资助金额:
    $ 25.6万
  • 项目类别:
Study for the development of ethical fuidelines and review methodology for non-medical human subject research at Universities
大学非医学人类课题研究的道德准则发展和审查方法研究
  • 批准号:
    21K13658
  • 财政年份:
    2021
  • 资助金额:
    $ 25.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Human Subject Core
人类主体核心
  • 批准号:
    10379916
  • 财政年份:
    2021
  • 资助金额:
    $ 25.6万
  • 项目类别:
Human Subject Core
人类主体核心
  • 批准号:
    10091061
  • 财政年份:
    2021
  • 资助金额:
    $ 25.6万
  • 项目类别:
Characterizing and Restoring Joint Motion in Patients with Hallux Rigidus: Human Subject Testing
拇强直患者的关节运动特征和恢复:人体测试
  • 批准号:
    10710384
  • 财政年份:
    2020
  • 资助金额:
    $ 25.6万
  • 项目类别:
Characterizing and Restoring Joint Motion in Patients with Hallux Rigidus: Human Subject Testing
拇强直患者的关节运动特征和恢复:人体测试
  • 批准号:
    10262929
  • 财政年份:
    2020
  • 资助金额:
    $ 25.6万
  • 项目类别:
Understanding Gender Bias in Human Subject Sampling in HCI Research
了解人机交互研究中人类受试者抽样中的性别偏见
  • 批准号:
    542746-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 25.6万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了